UK biotech fundraising picks up with best quarterly total since 2021

London, United Kingdom, 9 November 2023 - The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

This represents a 48% increase from the previous quarter's takings and consistent quarter-on-quarter growth throughout the year making this the most robust period since the sector’s peak in 2021. This is in line with the surge in fundraising activity among European companies that more than doubled their fundraisings this quarter, while US companies saw a 21% decline across all fundraisings.

While the dearth of public market launches continues to present challenges for European companies, including UK biotech companies, public follow-on financings were responsible for the increased investment this quarter, with UK companies raising a total of £315 million after a year of subdued activity.

Venture capital funding amounted to £249 million, representing a 26% decline compared to the previous quarter but still a 35% increase from the same period last year. Although fewer deals took place, early-stage companies were well-supported, with many deals falling into seed and series A categories.

Steve Bates OBE, CEO of the BIA, said:

"Against a difficult economic backdrop, the quality of the science and management teams in UK biotech is continuing to attract domestic and foreign investors. Strong seed and Series A dealmaking bodes well for company formation through 2023 and UK biotechs remain the European leaders for total venture capital raised. With the Jefferies London Healthcare conference becoming the pre-eminent global life sciences financing conference, all eyes are on the UK, and it is great to see us demonstrating success.

New initiatives stemming from the Mansion House Agreement help to give confidence for the UK financing ecosystem, with pension savers well placed to benefit if the pensions industry engages with this UK success story.”

“Globally, 2023 remains challenging for biotech, with the IPO window still closed. However, this quarter's total of £563 million is the highest we've seen since the record-breaking year of 2021 and is an encouraging sign that the global funding malaise is starting to recede. "

Mike Ward, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate, said:

"With world events such as wars in Ukraine and the Middle East and geopolitical tensions and the macroeconomic headwinds of persistent high-interest rates, it is hardly surprising that there has been a flight from riskier asset classes.

“Even though big pharma is sitting on big cash piles, and venture capitalists have billions in dry powder, there has been a reluctance to deploy the capital. Consequently, across the globe, biotech companies have struggled to raise new money.

“On a more positive note, we are seeing more enthusiasm for licensing and M&A deals as big pharma looks to replenish its pipelines.”  

The encouraging report follows recent efforts to unlock capital from pension funds to further boost investment into high-growth and innovative companies propelling the UK's life sciences sector to surpass last year's total fundraisings.

In his Autumn Statement, Chancellor Jeremy Hunt is expected to unveil a government initiative aimed at turbocharging pension funds' investments in high-growth private companies, one of the key goals of the Mansion House compact launched earlier this year.


Notes to Editors


About the BioIndustry Association (BIA)

The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow, and deliver world-changing innovation.

Helping biotech and life sciences sector to influence, connect and save. 


More news and updates 

BIA responds to the Chancellor's Autumn Statement 2023

Life science spin-outs, start-ups and scale-ups are key drivers of the UK’s innovation-based economy and crucial for discovering and developing new medicines to save lives in the NHS. The UK is home to a third of life science startups founded in Europe since 2012 and companies like them are responsible for nearly two-thirds of medicines being developed globally.

bioProcessUK to celebrate biotech’s shining stars 

The BioIndustry Association (BIA) will honour two distinguished individuals for their exceptional contributions to the innovative life sciences and biotech sector.

UK biotech fundraising picks up with best quarterly total since 2021

The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

Rare disease companies call for UK leadership in supporting access to new treatments

A group of companies developing innovative new medicines for rare diseases, working together through their trade association, is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice both in the UK and internationally, to improve access to new treatments for patients.

UK TechBio driving AI revolution in drug discovery and patient care

AI, gene editing, engineering biology, and investor interest drive growth in UK bioeconomy.

UK set to lead global delivery of next-generation mRNA medicines

BIA's new explainer shows how the UK is leading the way in mRNA, a strategic technology of the future.

UK Regulatory Science community meets to discuss the future of UK Medicine Regulation

Leaders in medicines regulatory science are meeting to chart the course for the future of UK medicine regulation on 5 October at 11 Cavendish Square, London. 

UK biotech investment increases amidst progress in City of London to unlock new capital

The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, as revealed by new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of capital in the City of London.

BIA is first occupier at Victoria House, London’s life sciences hub

Oxford and Pioneer Group launch plans for central London's largest office-to-life sciences conversion project, securing first lease with BIA.

BIA joins UK Health Data Research Alliance

The BioIndustry Association (BIA) joins the UK Health Data Research Alliance as a member, alongside UK national data custodians, NHS foundation trusts and research institutes to help develop best practice around the ethical use of health data. 


More within